A novel lectin-independent interaction of P fimbriae of Escherichia coli with immobilized fibronectin  by Westerlund, Benita et al.
Volume 243, number 2, 199-204 FEB 06716 January 1989 
A novel lectin-independent interaction of P fimbriae of Escherichia 
coli with immobilized fibronectin 
Benita Wester lund,  Pentt i  Kuuse la  +, Tap io  Vart io*,  I rma van Die ° and T imo K. Korhonen 
Departments ofGeneral Microbiology, +Bacteriology and Immunology and * Pathology, University of Heisinki, 
Mannerheimintie 172, SF-O0300 Helsinki, Finland and o Department ofMolecular Cell Biology, University of Utrecht, 
Utrecht, The Netherlands 
Received 29 November 1988 
Binding of P fimbriae of uropathogenic Escherichia coil to purified human plasma flbronectin and human placental type 
IV collagen was studied. In an enzyme immunoassay, purified P fimbriae bound strongly to immobilized intact fibronectin 
and to the aminoterminal 30-kDa fragment and the 120-140-kDa c rboxyterminal fr gments offibronectin. Binding to 
the gelatin-binding 40-kDa fragment offibronectin was considerably weaker. No binding to immobilized type IV collagen 
was seen. The interaction between P fimbriae and immobilized flbronectin was not inhibited by ,,-D-GaI-( 1-4)-fl-D-Gal-1- 
O-Me, a receptor analog of P funbriae. Moreover, amutated P fimbria lacking the lectin activity behaved similarly in 
the adherence assays. Recombinant strains expressing the corresponding cloned fimbriae genes bound to immobilized 
fibronectin, but no binding to soluble ~'5I-labelled fibronectin was found. The results uggest that P fimbriae interact 
with immobilized fibronectin and that he binding mechanism does not involve the lectin activity of the flmbriae. 
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1. INTRODUCTION 
P fimbriae are a major virulence factor of 
Escherichia coli strains associated with human 
childhood pyelonephritis [1]. They bind to tubular 
epithelia and vascular endothelium in the kidney 
and to epithelia of the lower urinary tract of 
humans [2]. P fimbriae are thought o increase the 
virulence of E. coli by mediating bacterial 
adherence to epithelial glycoconjugates, thus giv- 
ing resistance to mechanical clearance by the flow 
of urine. The receptor structure recognized by P- 
fimbriated E. coli is the disaccharide moiety ot-D- 
Gal-(1-4)-~-D-Gal of the P-blood-group antigens 
[31. 
Fibronectin (FN) is a 450-kDa dimeric glycopro- 
tein found in a soluble form in body fluids, such 
as blood plasma, and as an insoluble protein in the 
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extracellular matrix and in association with base- 
ment membranes [4-6]. One of the main biological 
functions of FN is to promote attachment and 
spreading of eukaryotic cells on different 
substrates. FN is also important in wound healing 
and involved in clot stabilization. A characteristic 
of FN is its ability to interact with a wide variety 
of mammalian molecules and cells [4-6]. 
The FN molecule is composed of two nearly 
similar polypeptides joined by two disulfide 
bridges at the carboxytermini. Over 90°70 of the 
molecule consists of repeats of three types of fairly 
homologous amino acid sequences. On the basis of 
binding properties, the two chains of FN can be 
divided into functional domains. So far, many 
specific domains have been identified, including 
those binding to fibrin, heparin, collagen, gelatin, 
DNA and several bacterial species [5]. A specific 
cell-attachment domain containing the sequence 
Arg-Gly-Asp-Ser in FN is recognized by 
fibroblasts, platelets and other eukaryotic cells 
[5,6]. 
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Kuusela [7] described the binding of 125I- 
labelled, soluble FN to Staphylococcus aureus. 
Thereafter, many Gram-positive bacteria, in- 
cluding group A, C and G streptococci [8-10] and 
strains of staphylococci [11 ] were shown to interact 
with soluble FN. Moreover, recently certain 
human and animal isolates of E. coli [12-14] and 
strains of Salmonella [15] have also been found to 
bind FN. The FN-binding protein of S. aureus has 
recently been identified and its gene cloned [16]. 
Recent genetic work has shown that the P- 
fimbrial filament of E. coli is composed of a major 
structural subunit, fimbrillin, and of minor com- 
ponents that are responsible for the lectin activity 
of the filament [17]. These lectin-like molecules 
probably are situated at the tip of the filament 
[18], and it is thought hat the function of fim- 
brillins is to expose the lectin molecules of the fim- 
briae beyond the lipopolysaccharide and capsular 
layers of the bacterial cell [19]. In this communica- 
tion we show that P fimbriae of E, coli, both on 
bacterial cells and as purified proteins, interact 
with immobilized FN and its fragments. The 
binding is independent of the lectin activity of the 
P fimbriae. This work was presented in part at the 
88th ASM meeting in Miami, USA, 8-13 May 
1988. 
2. MATERIALS AND METHODS 
2.1. Bacteria 
E. coli HBI01 and the recombinant s rains carrying cloned 
genes for the wild-type P (F71) fimbriae [HBI01(pP1L110-75)] 
or for the lectin-deficient P fimbriae [HB101(pPILI10-7501)] 
have been described before [20,21]. The strain IHl1128, 
possessing the O75X adhesin, has previously been characterized 
for its adhesins and binding properties [22,23]. The bacteria 
were grown overnight at 37°C on Luria agar plates sup- 
plemented with ampiciUin for the recombinant strains. For 
adhesion tests, the bacteria were collected, washed with 
phosphate-buffered saline (PBS) and finally suspended in PBS 
containing 0.1070 (w/v) bovine serum albumin (BSA; Sigma, St. 
Louis, MO, USA) (PBS-BSA 0.1070). For purification of fim- 
briae, the recombinant s rains were grown for 48 h at 37°C in 
Luria broth supplemented with ampicillin. 
2.2. Purified proteins and the antisera 
The purified O75X adhesin and the antiserum against it have 
been described earlier [22,23]. P fimbriae were purified from 
strains HBI01(pPIL110-75) and HB101(pPILI10o7501) using 
deoxycholate and Concentrated urea [24]. Antiserum against the 
F7~ fimbriae has been described [25]. Human plasma FN was 
purified by the method of Engvall and Ruoslahti [26] using the 
modification of Vuento and Vaheri [27]. The purified 30-kDa, 
40-kDa and 120-140-kDa fragments of FN were as in previous 
work [28,29]. Fetuin and human placental type IV collagen 
were from Sigma. 
2.3. Binding tests with purified fimbriae 
The binding of the purified P fimbriae and the O75X adhesin 
(50/zg/ml) to polystyrene microtiter plates coated with FN, type 
IV collagen or fetuin (25/zg/ml) was tested by enzyme-linked 
immunosorbent technology as detailed elsewhere [22,23]. Ab- 
sorbance values in independent duplicates were in general 
within 10070 of the mean. In inhibition experiments, D-glucose 
(Merck, Darmstadt, FRG) and ot-D-GaI-(I-4)-B-D-GaI-I-O-Me 
(Biocarb Chemicals, Lund, Sweden) were tested at 25 mM final 
concentration, and tetrapeptides Arg-Gly-Asp-Ser or Val-Ala- 
Ala-Phe (Sigma) at 5 mM final concentration. 
2.4. Adhesion assay with intact bacteria 
Glass slides with ground-edged areas (Chance Propper Ltd, 
Warley, England) were coated for 16 h at 22°C with the 
glycoproteins to achieve a final coating concentration of 
5 pmol/area. For fetuin, a coating concentration of 50 #g/ml 
was used. Data for quantitative coating with the glycoproteins 
was available from previous work [23]. The slides were washed 
three times for 5 min in PBS-BSA (0.1070) and consequently 
saturated with PBS-BSA (20/o) for 2 h at 22°C. Then the slides 
were overlaid with bacteria (3 x 101° cells/ml in 0.1070 PBS- 
BSA; 50/~l/ground-edged area) for 5 h at 22°C. In inhibition 
tests, ot-D-Gal-(1-4)-B-D-Gal-l-O-Me or D-glucose (both at a 
final concentration f 25 mM) were incubated together with the 
bacterial suspensions. After incubation with bacteria the slides 
were washed three times with 0.1070 PBS-BSA and dried at 
22°C. Finally, the adhered bacteria were visualized by staining 
with methylene blue (Merck) and quantitated by counting the 
number of bacteria in 20 randomly chosen microscopic fields. 
The area of one field was 4.8 × 103/~m 2.
2.5. Binding of  radiolabelled glycoproteins to bacteria 
FN and type IV collagen were labelled with carrier-free 
Na1251 (Amersham, Buckinghamshire, England and New 
England Nuclear, Boston, MA, USA) using the Iodogen [30] 
(Pierce, Rockford, USA) and the chloramine T methods [31]. 
The specific activity obtained ranged from 2.5 to 3.6/~Ci//zg of 
protein. The binding assay was performed as detailed in [23]. 
Briefly, 5 x 107 bacterial cells were mixed with 5 ng of labelled 
protein in 300/~1 of 1070 PBS-BSA for 1.5 h at 22°C. After two 
washed with 1 070 PBS-BSA, the bound radioactivity was quan- 
titated in a 1270 Rackgamma II counter (LKB, Bromma, 
Sweden). 
3. RESULTS AND DISCUSSION 
Systematic studies on the interaction between 
various purified fimbriae and extracellular matrix 
components have revealed that the O75X adhesin 
of E. coli, which binds preferentially to basement 
membranes, strongly interacts with human type IV 
collagen [23]. Similar type of experiments also 
showed the interaction of P fimbriae with im- 
mobilized FN. 
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Purified P fimbriae bound efficiently to 
polystyrene microtiter wells coated with human 
plasma FN (fig. 1A). Absorbance values in control 
wells, which were processed i entically but without 
the fimbriae, were at the highest 1% of the positive 
test values (not shown). No significant binding of 
P fimbriae to immobilized type IV collagen or to 
the control protein fetuin was seen (fig.lA). The 
binding to FN was not inhibited by 25 mM ot-D- 
Gal-(1-4)-/3-D-Gal-l-O-Me (fig.lA and B), a 
receptor-analog forP fimbriae [3]. This concentra- 
tion is enough to inhibit binding of purified P fim- 
briae to human tissues [2]. The mutant fimbriae 
from strain HB101(pPIL110-7501), lacking the lec- 
tin activity, bound as efficiently and selectively to 
immobilized FN as did the 110-75 P fimbriae 
(fig. 1C). As a further control for the specificity of 
the binding, the purified O75X adhesin was includ- 
ed in the test. As found in earlier work [23], the 
O75X adhesin showed a strong binding to type IV 
collagen but only a weak binding, or none at all, 
to immobilized FN and fetuin (fig.lD). 
The intact FN molecule can be proteolytically 
cleaved into defined fragments. The 30-kDa 
aminoterminal fragment contains the binding do- 
mains for fibrin, heparin, S. aureus and strep- 
tococci, and the 40-kDa fragment next to the 
aminoterminus interacts with collagen and gelatin. 
The 120- to 140-kDa carboxyterminal fragment 
contains the cell-attachment domain and another 
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possible binding site for staphylococci and strep- 
tococci [5]. To localize the binding sites for P fim- 
briae within the FN molecule, these fragments 
were tested for the interaction. The P fimbriae 
from strain HB101(pPILl10-75)bound efficiently 
to the 30-kDa aminoterminal and the 
120-140-kDa carboxyterminal fragments of FN 
(fig.2). Only a weak interaction with the gelatin- 
binding 40-kDa fragment was seen (fig.2). 
The adherence of the 110-75 fimbriae to solid- 
phase intact FN or to the 30-kDa and 
120-140-kDa fragments of FN was not inhibited 
by the tetrapeptides Arg-Gly-Asp-Ser (the cell- 
attachment sequence of FN [6]) or Val-Ala-Ala- 
Phe (a test control), both tested at 5 mM (not 
shown). This concentration of the Arg-Gly-Asp- 
Ser peptide is enough to inhibit adhesion of normal 
rat kidney cells to immobilized intact FN [6]. 
To confirm the binding results obtained with 
purified fimbriae, the adhesion of intact bacterial 
cells to glycoproteins immobilized on glass slides 
was determined. The recombinant strain 
HB101(pPILl10-75), carrying wild-type P tim- 
briae genes, adhered about ten times more effi- 
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Fig.1. Binding of purified P fimbriae to microwells coated with 
FN (bar l), type IV collagen (bar 2) and fetuin (bar 3). (A) 
Binding of the 110-75 fimbriae in the presence of 25 mM D- 
glucose and (B) in the presence of 25 mM ot-D-Gal-(1-4)-/~-D- 
Gal-l-O-Me. (C) Binding of the lectin-deficient 110-7501 
fimbriae. For comparison, binding of the type-IV-collagen- 
binding O75X adhesin is also shown (D). 
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Fig.2. Binding of the purified 110-75 fimbriae to microwell~ 
coated with FN or its fragments. (Symbols) Bar l, FN; bar 2, 
the aminoterminal 30-kDa fragment; bar 3, the gelatin-binding 
40-kDa fragment; bar 4, the 120-140-kDa carboxyterminal 
fragment; bar 5, fetuin. 
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ciently to slides coated with FN than to those 
coated with type IV collagen or fetuin (fig.3A). 
The adhesion was not inhibited by 25 mM a-D- 
Gal-(1-4)-ff-D-Gal-l-O-Me (fig.3B). The recombi- 
nant strain HB101(pPILl10-7501), expressing the 
mutated P fimbriae genes, showed the same 
binding pattern (fig.3C). The control strain E. coli 
HB101, lacking fimbriae, did not adhere to FN 
(fig.3D). For comparison, the adhesion of the 
O75X-positive strain IHll128 is also shown 
(fig.3E). As expected from earlier work with 
purified O75X adhesin [23], the strain bound effi- 
ciently to type IV collagen, more weakly to FN and 
not at all to fetuin. 
We next tested binding of ]25I-labelled FN and 
type IV collagen to the recombinant bacteria. No 
significant binding of 125I-labelled FN was seen 
with either HB101, HB101(pPILl10-75) or 
HB101(pPILl10-7501) cells (not shown). The 
iodination methods used had no effect on the 
result. However, in similar experiments, he O75X- 
positive strain IH11128 bound 125I-labelled type IV 
collagen efficiently but failed to bind soluble FN 
[23]. 
Our results show that P fimbriae of 
uropathogenic E. coli interact with immobilized 
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Fig.3. Adhesion of recombinant bacteria to FN (bar 1), type IV 
collagen (bar 2) and fetuin (bar 3). (A) Adhesion of strain 
HBIOI(p110-75) in the presence of 25 mM D-glucose and (B) in 
the presence of 25 mM a-D-GaI-(I-4)-B-D-Gai-I-O-Me. (C) 
Adhesion of the strain HBI01(p110-7501) expressing mutated P 
fimbriae genes. (D) Adhesion of the strain HBI01 lacking 
fimbriae. (E) Adhesion of the O75X-positive strain IHI 1128. 
Bacteria in twenty randomly chosen fields of 5 x 103 #m 2 were 
counted in each case, standard eviations are also shown. 
FN. Specificity of the interaction is indicated by 
lack of P-fimbriai binding to immobilized type IV 
collagen or fetuin (fig. 1), and by the finding that 
recombinant bacteria expressing the corresponding 
fimbriae showed similar adhesion patterns (fig.3). 
Adhesion of the fimbriated E. coli strains to im- 
mobilized FN was weak but repeatable and con- 
stantly higher than that of the recipient strain 
HB101. Moreover, the O75X adhesin of E. coli 
which is known to interact with type IV collagen 
[23], did not show binding to FN (figs 1 and 3), in- 
dicating target specificity in our test systems. The 
findings that the interaction of the wild-type P fim- 
briae with FN was not inhibited by o~-D-GaI-(I-4)- 
~-D-GaI-1-O-Me (figs IA,B and 3A,B), and that 
the interaction was seen also with the 110-7501 
fimbriae lacking the lectin activity (figs 1C and 
3C), strongly suggest that this novel interaction is
independent of the lectin activity of the P-fimbrial 
filament. At present, it is impossible to say 
whether the P-fimbrial filament is recognized by 
FN, which is known to possess several binding 
properties, or whether the fimbrillin subunits have 
binding properties of their own, i.e. independently 
of the oe-D-Gal-(1-4)-B-D-Gai binding via the 
lectin-like minor components of the filament. 
Interestingly, the interaction between P fimbriae 
and FN appears to involve mainly the aminoter- 
minal 30-kDa and the carboxyterminal 120- 
140 kDa fragments (fig.2) that interact also with 
staphylococci and streptococci [5]. Whether these 
bacteria use the same or different binding site(s) in- 
side each domain remains till to be resolved. The 
interaction does not seem to involve the cell- 
binding domain of FN, as the tetrapeptide Arg- 
Gly-Asp-Ser was not inhibitory. 
Although P fimbriae interacted readily with the 
immobilized form of FN (figs 1-3), no binding of 
soluble, 125I-labelled FN to  bacteria expressing the 
same P fimbriae was seen. In this respect, the in- 
teraction described here differs from binding of 
FN to S. aureus and group G streptococci, which 
can be detected with the soluble and insoluble 
forms of FN [7-11]. Moreover, binding of 125I- 
labelled, soluble FN to E. coil cells [12-14] and to 
fimbriae of Salmonella enteritidis [32] have been 
reported. This suggests that E. coil has several 
mechanisms for interaction with FN, one active 
only with the insoluble form and the other with 
both soluble and insoluble forms of FN. 
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Interaction of  P fimbriae with FN has parallel 
phenomena involving only the insoluble form of  
FN. S. sanguis adheres to FN immobilized on 
gelatin-coated plastic hut does not bind soluble FN 
[33]. Similarly, plasminogen [34] and hyaluronate 
[35] bind to immobilized FN but not to soluble FN. 
Interestingly, group A streptococci show a re- 
versed binding property: they bind soluble FN but 
adhere poorly to FN-coated glass surfaces [36]. 
These differences are best explained by conforma- 
tional differences between the soluble and the in- 
soluble forms of  FN. Soluble FN exists in a 
globular configuration with the aminotermini of  
the two chains folded inwards. Upon immobiliza- 
tion, the chains unfold and the molecule has a 
linear configuration [37]. 
Our  results have an important conclusion for the 
pathogenetic role of  P fimbriae in human upper 
urinary tract infections. So far, it has been thought 
that the function of  P fimbriae is to mediate 
bacterial attachment o the a-D-Gal-(1-4)-B-D- 
Gal-containing lycoconjugates o f  human epithe- 
lial and endothelial cells [2,3] and that the fim- 
brillins are needed to carry the lectin molecules 
beyond l ipopolysaccharide and capsular layers of  
the bacterial cell wall [19]. Our results suggest o f  a 
further function for the P fimbriae: they interact 
with a component o f  the extracellular matrix in a 
manner that is independent o f  a-D-Gal-(1-4)-fl-D- 
Gal binding. Such interaction can be useful for the 
bacteria at later stages of  the infection, i.e. after 
epithelial t rauma and exposure of  connective tissue 
when the ascent o kidneys has taken place and the 
lectin activity o f  the fimbriae is perhaps not useful 
anymore. 
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